Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Cyclophosphamide hikma manufacturer?

See the DrugPatentWatch profile for Cyclophosphamide

Cyclophosphamide – Hikma Pharmaceuticals

Item Details
Manufacturer Hikma Pharmaceuticals Ltd.
Brand names (generic) Cyclophosphamide (often sold under brand names such as Cytoxan in the U.S., Cyclophospham in the EU, and other local generic names)
Formulations IV infusion solution, oral tablets (often 50 mg, 100 mg, 250 mg, 500 mg, 750 mg, and 1 g), and injectable suspension for subcutaneous use (rare).
Indications • Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, vasculitis)
• Hematologic malignancies (non‑Hodgkin’s lymphoma, multiple myeloma, Hodgkin’s lymphoma)
• Solid tumors (e.g., breast cancer, ovarian cancer) as part of combination chemotherapy
• Certain dermatologic conditions (e.g., severe atopic dermatitis, psoriasis)
• Adjunct in stem‑cell transplantation protocols
Key regulatory approvals • FDA‑approved (generic and brand) for IV and oral formulations.
• EMA‑approved for oral tablets (generics) and IV infusion.
• Approved by many national regulatory agencies (e.g., TGA in Australia, MHRA in the UK).
Production sites Hikma operates manufacturing facilities in multiple countries, including the United Kingdom (Luton), the United States (St. Louis, Missouri), the Middle East (Jordan, Saudi Arabia), and the United Kingdom (Sheffield). The cyclophosphamide production is typically performed in GMP‑certified facilities that meet EU, FDA, and other international standards.
Packaging • IV infusion solution: 500 mg/5 mL ampoules (1 g/10 mL).
• Oral tablets: 50 mg, 100 mg, 250 mg, 500 mg, 750 mg, 1 g.
• Sterile packaging with tamper‑evident seals; shelf life typically 2–3 years under proper storage.
Availability Widely available as a generic in many markets. The brand “Cytoxan” is marketed by other manufacturers, but Hikma supplies the generic oral and IV forms for most national formularies.
Patients often receive cyclophosphamide through oncology departments or rheumatology clinics, where the drug is prepared and administered under strict protocols.

A Few Points to Keep in Mind

Topic Key Take‑aways
Dosing The dose is usually calculated by body surface area (BSA). For example, 2 mg/kg IV once or twice a week for many chemotherapies, or 50 mg/kg IV weekly in rheumatology protocols. Oral dosing often follows the same BSA‑based approach or fixed‑dose schedules (e.g., 50 mg × 7 days).
Common side effects Myelosuppression, nausea/vomiting, alopecia, bladder irritation (hematuria), cardiotoxicity (rare but dose‑dependent). Monitoring CBC, electrolytes, and renal function is standard.
Contraindications Severe hepatic/renal impairment, active infection, pregnancy (teratogenic), uncontrolled bleeding disorders.
Special precautions Avoid exposure to sunlight after high‑dose regimens, use of bladder protection (hydration + mesna for high‑dose). Counsel patients on the risk of secondary malignancies and the need for long‑term follow‑up.

How to Get It

  1. Prescription – Cyclophosphamide must be prescribed by a qualified physician (oncologist or rheumatologist).
  2. Pharmacy – Most hospitals, oncology centers, and large community pharmacies can dispense Hikma’s generic version.
  3. Insurance – Verify coverage: many health plans cover the generic due to lower cost compared with brand‑name formulations.
  4. Patient Assistance – Hikma sometimes offers patient assistance or co‑pay programs for patients with financial barriers. Check the Hikma website or call your local pharmacy for details.

Quick Reference

  • Generic name: Cyclophosphamide
  • Manufacturer: Hikma Pharmaceuticals
  • Common dosage forms: Oral tablets (50–1 g), IV solution (500 mg/5 mL).
  • Typical uses: Autoimmune disease flare control, chemotherapy for lymphoma, breast/ovarian cancers, etc.
  • Key safety note: Always monitor blood counts and organ function; counsel patients on sun‑safety and bladder protection.

If you have a specific dosing question, a side‑effect concern, or need help locating a Hikma pharmacy in your area, let me know!



Other Questions About Cyclophosphamide :

Cyclophosphamide cost? Cyclophosphamide orange book patent expiration dates? Cyclophosphamide brand? Cyclophosphamide pharmaceutical brand? Cyclophosphamide 50 mg price? Pharmaceutical companies manufacturing cyclophosphamide? Cyclophosphamide patent expiration date 2036?

AI-Drug Label Prescribing Information Alignment Report

25
25%
Grade D

Poor

Not Aligned

Patient Risk: Low

Summary

The submitted claims about multiple manufacturers (Hikma, Teva, Sandoz, Fresenius Kabi, Sun Pharma, Lupin) and country-specific packaging are not supported by the label content, which only references Baxter as the manufacturer. Several claims are missing or mischaracterize the label. The evaluation indicates substantial misalignment.

Category Scores

Accurate Statements

Unsupported Statements

Hikma Pharmaceuticals does manufacture cyclophosphamide for injection as part of its generic injectable portfolio.
Availability and packaging vary by country.
Cyclophosphamide is made by several other manufacturers as well.
Teva is a manufacturer of cyclophosphamide for injection in some regions.
Sandoz is a manufacturer of cyclophosphamide for injection in some regions.
Fresenius Kabi is a manufacturer of cyclophosphamide for injection in some regions.
Sun Pharma is a manufacturer of cyclophosphamide for injection in some regions.
Lupin is a manufacturer of cyclophosphamide for injection in some regions.
Cyclophosphamide is made by several other manufacturers as well.
All listed manufacturers (Hikma, Teva, Sandoz, Fresenius Kabi, Sun Pharma, Lupin) produce cyclophosphamide for injection in some regions.

Contradictions

Important Omissions

Baxter is the manufacturer per the label; claims did not mention Baxter, ignoring the label's actual manufacturer.
Importance: High

Safety Assessment

Potential Patient Risk: Low
Misalignment relates to non-clinical labeling claims; no patient-specific safety risk arises from these misstatements alone.

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Not Aligned

Primary Issue
Claims incorrectly assert multiple manufacturers and country-specific packaging not supported by the label; Baxter is the only manufacturer identified in the provided label.

Suggested Improvement
Limit manufacturer claims to Baxter as indicated on the label; avoid asserting other named manufacturers or country-specific packaging variations unless explicitly stated in the label. If discussing packaging, reference the specific vial sizes and NDCs shown in the label and avoid general country-based statements.

Drug Brand Mention Assessment

Branding Score
51
Visibility
44
Mentioned
Ranking
#2
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

manufacturing cyclophosphamide for injection

Core Claims
  • Hikma Pharmaceuticals does manufacture cyclophamide for injection as part of its generic injectable portfolio.
  • Availability and packaging vary by country.
  • Cyclophosphamide is made by several other manufacturers as well (Teva, Sandoz, Fresenius Kabi, Sun Pharma, Lupin, etc.), depending on the region and formulation.
  • If you have a specific vial or lot, share the country, packaging size, or the label/NDC, and I can help confirm the exact manufacturer for that product.
Differentiators
  • manufacture cyclophosphamide for injection
  • generic injectable portfolio
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Teva 44%
50 #3 No
Sandoz 44%
50 #4 No
Fresenius Kabi 44%
50 #5 No
Sun Pharma 44%
50 #6 No
Lupin 44%
50 #7 No